Clinical trials of polycythemia vera and essential thrombocythemia patients with lestaurtinib, a multikinase inhibitor of JAK1, JAK2, JAK3, FLT3 and TRKA/B/C has shown to modestly reduce JAK2-V617F allele burden and spleen size [80,87]. This evidence concerns the gene JAK2 and essential thrombocythemia.